Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06306781
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-12
First Post:
2024-01-31
Brief Title:
A Clinical Trial Evaluating the Safety Tolerability and Preliminary Efficacy of HCL001 Cell Injection Homologous Allogeneic Hepatocytes in Patients With Decompensated Cirrhosis
Sponsor:
RenJi Hospital
Organization:
RenJi Hospital
Study Overview
Official Title:
Clinical Trial Evaluating the Efficacy of Homologous Allogeneic Hepatocytes in Patients With Decompensated Cirrhosis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study protocol is designed to evaluate the clinical efficacy safety and tolerability of HCL001 cell injection in the treatment of decompensated cirrhosis The aim is to provide stronger evidence for the clinical application of HCL001 cell injection in the treatment of decompensated cirrhosis thereby attempting to improve patients survival and quality of life to meet the clinical needs for treating decompensated liver cirrhosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None